RBC Capital Maintains Outperform on Karuna Therapeutics, Lowers Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Karuna Therapeutics (NASDAQ:KRTX), but lowered the price target from $235 to $225.
November 03, 2023 | 6:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna Therapeutics' price target has been lowered from $235 to $225 by RBC Capital, though the 'Outperform' rating is maintained.
The news of a lowered price target could potentially have a negative impact on the stock price in the short term as it may cause investors to reassess their positions. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100